Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Athersys (ATHX) Competitors

Athersys logo
Compare

ATHX vs. DCOY, VCNX, ORGS, CANF, and ASLN

Should you buy Athersys stock or one of its competitors? MarketBeat compares Athersys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athersys include Decoy Therapeutics (DCOY), Vaccinex (VCNX), Orgenesis (ORGS), Can-Fite BioPharma (CANF), and ASLAN Pharmaceuticals (ASLN).

How does Athersys compare to Decoy Therapeutics?

Athersys (NASDAQ:ATHX) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Decoy Therapeutics has lower revenue, but higher earnings than Athersys. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athersys$146K0.00-$72.53M-$2.03N/A
Decoy TherapeuticsN/AN/A-$12.52M-$106.90N/A

19.4% of Athersys shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 0.3% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 310.96%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Athersys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athersys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Decoy Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

In the previous week, Decoy Therapeutics had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for Decoy Therapeutics and 0 mentions for Athersys. Athersys' average media sentiment score of 0.00 equaled Decoy Therapeutics'average media sentiment score.

Company Overall Sentiment
Athersys Neutral
Decoy Therapeutics Neutral

Athersys' return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AthersysN/A N/A -223.03%
Decoy Therapeutics N/A -395.42%-193.30%

Summary

Decoy Therapeutics beats Athersys on 8 of the 13 factors compared between the two stocks.

How does Athersys compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Company Net Margins Return on Equity Return on Assets
VaccinexN/A N/A -383.58%
Athersys N/A N/A -223.03%

Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccinex$388K6.70-$20.25M-$48.27N/A
Athersys$146K0.00-$72.53M-$2.03N/A

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company Overall Sentiment
Vaccinex Neutral
Athersys Neutral

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 51.5% of Vaccinex shares are held by insiders. Comparatively, 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Vaccinex beats Athersys on 5 of the 8 factors compared between the two stocks.

How does Athersys compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Orgenesis has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company Overall Sentiment
Orgenesis Neutral
Athersys Neutral

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by company insiders. Comparatively, 0.0% of Athersys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Orgenesis has higher revenue and earnings than Athersys. Orgenesis is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$662K4.61-$55.36M-$11.51N/A
Athersys$146K0.00-$72.53M-$2.03N/A

Athersys has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Orgenesis-3,827.81% N/A -130.18%
Athersys N/A N/A -223.03%

Summary

Orgenesis beats Athersys on 6 of the 9 factors compared between the two stocks.

How does Athersys compare to Can-Fite BioPharma?

Athersys (NASDAQ:ATHX) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Company Net Margins Return on Equity Return on Assets
AthersysN/A N/A -223.03%
Can-Fite BioPharma N/A N/A N/A

Can-Fite BioPharma has higher revenue and earnings than Athersys. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athersys$146K0.00-$72.53M-$2.03N/A
Can-Fite BioPharma$405K5.50-$7.63M-$35.80N/A

Athersys has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Can-Fite BioPharma has a consensus price target of $42.50, suggesting a potential upside of 1,150.00%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than Athersys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athersys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Can-Fite BioPharma had 3 more articles in the media than Athersys. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 0 mentions for Athersys. Can-Fite BioPharma's average media sentiment score of 0.67 beat Athersys' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Athersys Neutral
Can-Fite BioPharma Positive

19.4% of Athersys shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Can-Fite BioPharma beats Athersys on 11 of the 13 factors compared between the two stocks.

How does Athersys compare to ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ASLAN Pharmaceuticals has higher revenue and earnings than Athersys. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92N/A
Athersys$146K0.00-$72.53M-$2.03N/A

Athersys' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN PharmaceuticalsN/A -8,454.87% -121.60%
Athersys N/A N/A -223.03%

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company Overall Sentiment
ASLAN Pharmaceuticals Neutral
Athersys Neutral

Summary

ASLAN Pharmaceuticals beats Athersys on 6 of the 9 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHX vs. The Competition

Export
MetricAthersysPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$833K$918.77M$6.40B$12.31B
Dividend YieldN/A4.84%2.79%5.33%
P/E Ratio0.001.4520.9925.67
Price / SalesN/A118.79580.0698.76
Price / CashN/A20.0744.1356.16
Price / BookN/A7.5610.087.01
Net Income-$72.53M-$3.91M$3.56B$335.38M

Athersys Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATHX
Athersys
N/AN/AN/AN/A$833K$146KN/A24
DCOY
Decoy Therapeutics
2.2523 of 5 stars		$5.48
+3.4%		$30.00
+447.6%		N/A$2.82MN/AN/A20
VCNX
Vaccinex
N/A$1.03
-6.4%		N/A+51.5%$2.68M$388KN/A40
ORGS
Orgenesis
N/A$0.45
flat		N/A-99.8%$2.33M$662KN/A150
CANF
Can-Fite BioPharma
2.8629 of 5 stars		$3.46
+6.5%		$42.50
+1,128.3%		-83.4%$2.13M$405KN/A8

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ATHX) was last updated on 5/22/2026 by MarketBeat.com Staff.
From Our Partners
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
June 12: Elon Musk’s “Day-One Retirement Plan.”
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
I don't think Wall Street will warn you in time
Wall Street insiders move early. Everyone else finds out later. That gap gets especially dangerous during a Ch...
Trend Labs | Sponsoredtc pixel